Current Issue January 2012, Vol. 39, No. 1

Issue Highlights

  • Preparation and preclinical evaluation of 177Lu-nimotuzumab targeting epidermal growth factor receptor overexpressing tumors
    January 2012(Vol. 39 | No. 1 | Pages 3-13)

    Denis R. Beckford Vera, Sebastian Eigner, Katerina Eigner Henke, Ondrej Lebeda, Frantisek Melichar, Milos Beran

  • Comparison of therapeutic efficacy and biodistribution of 213Bi- and 211At-labeled monoclonal antibody MX35 in an ovarian cancer model
    January 2012(Vol. 39 | No. 1 | Pages 15-22)

    Anna M.E. Gustafsson, Tom Bäck, Jörgen Elgqvist, Lars Jacobsson, Ragnar Hultborn, Per Albertsson, Alfred Morgenstern, Frank Bruchertseifer, Holger Jensen, Sture Lindegren

  • Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors
    January 2012(Vol. 39 | No. 1 | Pages 23-34)

    Michael R. Zalutsky, Abraham Boskovitz, Chien-Tsun Kuan, Charles N. Pegram, Joanne Ayriss, Carol J. Wikstrand, Anne F. Buckley, Eric S. Lipp, James E. Herndon, Roger E. McLendon, Darell D. Bigner

  • Evaluation of 68Ga-labeled tracers for PET imaging of myocardial perfusion in pigs
    20 January 2012

    Miikka Tarkia, Antti Saraste, Tiina Saanijoki, Vesa Oikonen, Tommi Vähäsilta, Marjatta Strandberg, Christoffer Stark, Tuula Tolvanen, Mika Teräs, Timo Savunen, Mark A. Green, Juhani Knuuti, Anne Roivainen

  • Quantification of regional cerebral blood flow in rats using an arteriovenous shunt and micro-PET
    20 January 2012

    Takayuki Ose, Hiroshi Watabe, Takuya Hayashi, Nobuyuki Kudomi, Masaaki Hikake, Hajime Fukuda, Noboru Teramoto, Yasuyoshi Watanabe, Hirotaka Onoe, Hidehiro Iida

  • A historical perspective on the specific activity of radiopharmaceuticals: what have we learned in the 35 years of the ISRC?
    20 January 2012

    Suzanne E. Lapi, Michael J. Welch

  • Bombesin analogues for gastrin-releasing peptide receptor imaging
    20 January 2012

    Prasant K. Nanda, Usha Pandey, Brienne N. Bottenus, Tammy L. Rold, Gary L. Sieckman, Ashley F. Szczodroski, Timothy J. Hoffman, Charles J. Smith

  • In vitro and in vivo evaluation of a 64Cu-labeled NOTA-Bn-SCN-Aoc-bombesin analogue in gastrin-releasing peptide receptor expressing prostate cancer
    20 January 2012

    Jeffrey M. Craft, Ravindra A. De Silva, Kimberly A. Lears, Rebecca Andrews, Kexian Liang, Samuel Achilefu, Buck E. Rogers

    • View More Articles in Press...

On the Cover

Cover Image

New Issue Alert

Free Trial Issue

Impact Factor

© Journal Citation Reports 2010, published by Thomson Reuters

Submit Online

Nuclear Medicine and Biology now accepts electronic submissions. Click here for more information.

Publishing Information

Nuclear Medicine and Biology is published by Elsevier for the Society of Radiopharmaceutical Sciences.



Access this journal onSciVerse ScienceDirect

Journal Access

Full-text articles are available from 1995 to the present. Access to abstracts is complimentary. Access to full text is limited to SRS members as well as personal subscribers.

Activate Online Access

Print or Share This Page

About Nuclear Medicine and Biology

Nuclear Medicine and Biology publishes original research covering all aspects of radiopharmaceutical chemistry: synthesis, radiopharmacy, in vitro and ex vivo testing, and in vivo evaluation of molecular probes for PET, SPECT, planar imaging, and autoradiography. These multidisciplinary studies should demonstrate the mechanism of localization whether the radioactive substance is based on receptor, enzyme, tumor antigen, or other well-defined biochemistry. The study should also address the sensitivity of the probe to changes in biochemistry, although studies of mechanism alone are acceptable. Contributions on the subject of therapeutic radiopharmaceuticals also are appropriate provided that the specificity of labeled compound localization and therapeutic effect have been addressed. If the synthesis of a new radiopharmaceutical is submitted alone, then the uniqueness of the chemistry must be emphasized. Papers that describe instrumentation important to molecular imaging as well as papers describing translational clinical research and the issues of extending preclinical research to clinical studies are also welcome.

Society of Radiopharmaceutical Sciences

Society of Radiopharmaceutical Sciences is a multidisciplinary professional organization dedicated to the advancement of excellence in education and research in radiopharmaceutical chemistry and in the study and use of radiopharmaceuticals. The organization has been formed to foster meetings for the purpose of communicating and discussing information about radiopharmaceuticals as they apply to the better understanding and control of biological phenomena, both normal and pathological; to disseminate information concerning radiopharmaceutical sciences by sponsoring scientific and professional publications; and strive to improve the welfare of mankind by maintaining and advancing the highest possible standards of education, research, and the practice of radiopharmaceutical sciences.